The Influencer Lilly Gaddis has claimed that her YouTube channel has been demonetized for being “too pro-White.” Gaddis, who has a following of over 240,000 on X and over 60,000 on Instagram, ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

More than 25 years after The Matrix, Lilly Wachowski is not surprised by the right-wing misinterpretation of her and sister Lana Wachowski’s magnum opus. After the movie’s mind-opening “red pill” ...

Claude Monet’s paintings of his garden in Giverny, particularly his water lily pond, are considered some of the world’s most beautiful and soothing works of art. Reproductions are ubiquitous, hung on ...

The booming market for weight-loss drugs has propelled Eli Lilly LLY-1.19%decrease; red down pointing triangle to become the first pharmaceutical company to hit $1 trillion in market capitalization, ...

"The cloud that has been casting a shadow over the healthcare industry is slowly lifting. The Eli Lilly agreement, along with the Trump deal with Pfizer last month, is providing investors with much ...

Eli Lilly (LLY) remains a core holding at 7% of NAV, but I have trimmed my position by 50% after a 38.8% price return since purchasing earlier in 2025. I have taken the proceeds and increased my MP ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies to provide direct access to their popular obesity meds. Thursday morning, ...

Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using artificial intelligence to discover new drugs. The Indianapolis Big Pharma will combine Insilico’s Pharma ...

Eli Lilly has halted development of a phase 2 P2X7 inhibitor for pain, the company confirmed to Fierce Biotech, in the latest shakeup to a pipeline that has already seen significant pivots this year.

Eli Lilly LLY-2.61%decrease; red down pointing triangle reported higher third-quarter profit and raised its full-year outlook on surging demand for its GLP-1 weight-loss drugs, sending its shares ...